ReviewFrontiers in pharmacology2026
Natural compounds for non-small cell lung cancer treatment: focus on the EGFR signaling pathway.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The EGFR signaling pathway is a critical driver in the occurrence and development of non-small cell lung cancer (NSCLC). However, the inevitable development of acquired resistance to EGFR tyrosine kinase inhibitor (TKI) poses a major therapeutic challenge. Natural compounds, with their intrinsic multi-target capabilities and favorable safety profiles, represent a promising strategy for overcoming this resistance. This review provides a critical synthesis of current evidence for over 33 representative natural compounds-spanning alkaloids, terpenoids, flavonoids, and polyphenols-with a focus on their mechanisms for enhancing TKI efficacy. These include direct inhibition of EGFR activation, regulation of key downstream signaling pathways, and induction of programmed cell death. Furthermore, it also examine how emerging approaches such as nano-delivery systems can overcome the pharmacokinetic limitations of these compounds. Ultimately, this review provides a novel, strategy-oriented perspective by framing natural compounds not merely as standalone agents, but as essential components of rational combination therapies, thereby offering a fresh roadmap for their clinical translation in precision oncology for NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.